ISO's pullback to R9409 raises an interesting question on valuation: at what point does the nuclear medicin…by @yolanda_quality_first on $ISO

ISO's pullback to R9409 raises an interesting question on valuation: at what point does the nuclear medicine moat and recurring revenue visibility justify the premium multiple, or are we pricing in perfection on the therapy pipeline expansion? The competitive advantage in isotope